register

Human Resources

PAIG co-chairs reflect on industry progress in D&I with sights set on next phase goals

Health Industry Hub | January 17, 2022 |

Human Resources: In this Health Industry Hub podcast, Medicines Australia’s PAIG (Pharma Australia Inclusion Group) co-chairs reflect on their contribution during the uncertainties of 2020-2021, the key highlights and pharma industry accomplishments in diversity and inclusion (D&I), and the themes that will drive PAIG’s agenda for the next two years.

Fiona Sheppard is a Diversity, Equity & Inclusion Leader at Johnson & Johnson Family of Companies and Lee Davelaar is the Strategic Policy Manager at Pfizer.

In considering the PAIG program in the last two years, Fiona commented “What is highlighted is that we still have a lot of work to do. Whilst we have a two year program and we’ve focused on flex, gender, First Nations, inclusion and mental health, we’re all on varying parts of the journey and there’s a lot to learn from each other. But we haven’t shifted the dial far enough on all of these things so that when they reset, they reset at a better place than where we were pre-COVID.”

“The mental health sessions and the First Nations sessions that we ran were definitely, I would say, the highlights from the two year program,” Fiona continued.

Lee discussed the PAIG leader’s workshop and the insights that will lead the program direction in 2022-2023. “A lot of organisations and members put their hand up and said we want deeper insights [in D&I]. They didn’t want to necessarily broaden the PAIG remit too much. We heard from organisations that they want to look at how they can see a commercial alignment with D&I objectives. There is still a great interest in hybrid and flexible working, and that the amalgamation of what we’re going to do in 2022 in terms of working from home and working in the office and how that’s going to work.”

You may also like: The compelling need to promote an age‑inclusive workforce, say PAIG co-chairs

He added “The development of the whitepaper is going to be a collaborative venture. We’re really excited that it’s now a piece of work with the University of Sydney Business School and PAIG project partner Willis Towers Watson. The research will be led by Professor Rae Cooper, Professor of Gender, Work and Employment Relations at the University of Sydney and undertaken by Troy Roderick, a Sydney Policy Lab fellow so passionate about this area. We expect to be able to be in a position to launch that late Jan – early Feb because that’s going to provide a platform for a lot of the 2022-2023 work for PAIG.”


News & Trends - Biotechnology

CSL reshapes R&D while bracing for U.S. tariffs

CSL reshapes R&D while bracing for U.S. tariffs

Health Industry Hub | July 11, 2025 |

Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]

More


News & Trends - MedTech & Diagnostics

Australia joins Medtronic trial in fight against resistant hypertension

Australia joins Medtronic trial in fight against resistant hypertension

Health Industry Hub | July 11, 2025 |

Medtronic has launched an international clinical trial across Australia, the United States, and Europe to evaluate the feasibility of multi-organ […]

More


News & Trends - MedTech & Diagnostics

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban

Health Industry Hub | July 11, 2025 |

Medibank has become the first Australian health insurer to pay towards pharmacogenetic testing (PGx) for eligible customers on Extras cover. […]

More


News & Trends - Pharmaceuticals

Global pledge shifts visibility and action for patients with advanced breast cancer

Global pledge shifts visibility and action for patients with advanced breast cancer

Health Industry Hub | July 11, 2025 |

Three breast cancer organisations have united internationally to demand that people living with metastatic breast cancer (MBC) are no longer […]

More


This content is copyright protected. Please subscribe to gain access.